Skip to Content

Generic Simbrinza Availability

Simbrinza is a brand name of brimonidine/brinzolamide ophthalmic, approved by the FDA in the following formulation(s):

SIMBRINZA (brimonidine tartrate; brinzolamide - suspension/drops;ophthalmic)

  • Manufacturer: ALCON RES LTD
    Approval date: April 19, 2013
    Strength(s): 0.2%;1% [RLD]

Has a generic version of Simbrinza been approved?

No. There is currently no therapeutically equivalent version of Simbrinza available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Simbrinza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Brinzolamide and brimonidine for treating glaucoma
    Patent 6,316,441
    Issued: November 13, 2001
    Inventor(s): Dean; Thomas R. & Desantis, Jr.; Louis & York; Billie M.
    Assignee(s): Alcon Manufacturing, Ltd.
    Methods and compositions for treating ocular conditions which find their etiology in compromised ocular blood flow with brinzolamide and brimonidine are disclosed.
    Patent expiration dates:
    • December 7, 2019
  • Aqueous pharmaceutical compositions containing borate-polyol complexes
    Patent 9,044,484
    Issued: June 2, 2015
    Assignee(s): Alcon Research, Ltd.
    The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate and a low concentration of benzalkonium chloride.
    Patent expiration dates:
    • October 30, 2030
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 19, 2016 - NEW COMBINATION


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.